A key reason positions haven't been filled is that they require travel that ranges from 25% to 75% of the time.

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

European Union antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings’ acquisition of contract drug ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

Pharmaceutical giant AstraZeneca has confirmed that Leon Wang, the head of its China operations, had been detained.

Pfizer (PFE, Financials) announced plans to invest $1 billion in China over the next five years to enhance research and ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially ...

Two current and two former senior AstraZeneca Plc executives in the group’s China unit are under investigation in a probe ...